Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Executive Chairman’s Welcome
- Belief Statement
- Our Founding Legacy
- Leadership
- Contact Us
- Message from the President and CEO
Patient Advocacy
- Patient Advocacy
- Rare Stories
- Patient Advisory Boards
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Global Research Center
Products
- Products & Services
- Galafold^®(migalastat)
- Pombiliti^™ + Opfolda^™(cipaglucosidase alfa-atga) (miglustat)
- AMICUS ASSIST^®
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

December 5, 2023

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

November 8, 2023

Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates

November 1, 2023

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023

October 27, 2023

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

October 3, 2023

Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

October 2, 2023

Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

September 28, 2023

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

September 1, 2023

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

August 29, 2023

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

August 21, 2023

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Our Products
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2023 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional